Neuronal acetylcholine receptor subunit alpha-6 (CHRNA6) (CHRNA6)

The neuronal acetylcholine receptor subunit alpha-6 (CHRNA6) is a key component of pentameric nicotinic acetylcholine receptors (nAChRs), ligand-gated ion channels that mediate fast synaptic transmission by allowing cation influx, particularly calcium, upon acetylcholine or nicotine binding. This subunit predominantly assembles with beta-2 (CHRNB2) and often alpha-4, beta-3, or others to form subtypes like α6β2, α4α6β2, and α6β2β3, which are highly expressed in dopamine-rich regions such as the ventral tegmental area (VTA), substantia nigra, locus coeruleus, striatum, and habenula, as well as in GABAergic, glutamatergic, noradrenergic neurons and astrocytes. These receptors modulate neuronal excitability, dopamine release, and reward signaling, contributing to processes like reinforcement learning and sensory processing. In disease, α6-containing nAChRs play a prominent role in nicotine addiction and substance use disorders by enhancing mesolimbic dopamine signaling, with emerging links to pain modulation via nociceptor expression and potential sex-specific vulnerabilities in habenular excitability. Drug interactions primarily involve nicotine as an agonist, alongside conotoxins and marine toxins that target subunit interfaces for antagonism, though therapeutic development is limited by poor surface trafficking requiring accessory proteins like NACHO and BARP. Overall, targeting α6β2* nAChRs holds promise for addiction therapies but faces challenges from their restricted distribution and addiction-promoting functions.

Other names

alpha-6 subunitα6 subunitCHRNA6

Ligand-gated cation channel activation (high calcium permeability upon acetylcholine or nicotine binding, leading to depolarization and neurotransmitter release); Agonist/antagonist binding at α-β subunit interfaces induces conformational changes for pore opening